Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: LT2011 who wrote (12384)	9/6/2013 12:08:26 PM
From: NTTG	1 Recommendation Recommended By Pogeu Mahone Read Replies (1) \| Respond to of 13111

If you look at the recent Seeking Alpha article you can see how unreal the hype is getting in the first few lines. While the orphan drug designation is true enough, the reality is that the pending PIII will be looking at a much less severe disease state. When you skip from orphan drug status to compassionate care w/o mentioning the long lost PII results, you know there is trouble in River City. PVCT is a research and innovation company...where did that come from? How much innovative research do they crank out in a given year? Not sure what 'significant recognition' is? Maybe it would be better if the oil and gas guys stuck with what they know, not what they hope for. Like the last news blurb to burp out of the machine, this one will not help SP Yea, Dr W was 'eased' out, they could have expanded the board and kept him in place